Developer docs
API playgroundTry for free, no card

Search company profiles

LyGenesis

Full company profile

uuid0000z49

Namestring
LyGenesis
Legal namestring
LyGenesis, Inc.
Websiteurl
lygenesis.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

LyGenesis is a clinical-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, developing allogeneic cell therapies that use a patient's own lymph nodes as in vivo bioreactors to grow functioning ectopic organs. The company's lead program, LYG-LIV-001, is an allogeneic liver cell therapy for end-stage liver disease currently in Phase 2a clinical trials (NCT04496479); one donated, otherwise-unmatched liver can potentially treat up to 75 patients via outpatient endoscopic ultrasound engraftment into mesenteric lymph nodes, upending the supply-demand economics of organ transplantation. The platform is being extended to additional organ programs: thymus regeneration (aging and immune tolerance, proof of concept completed), ectopic pancreas for Type 1 diabetes, ectopic kidneys for end-stage renal disease, and a combination drug-biologic product for inborn errors of metabolism led by Maple Syrup Urine Disease.

LyGenesis makes money, in the long run, by commercializing its cell therapies once clinical readouts and regulatory approvals are obtained; today it has no commercial revenue and no publicly disclosed pricing. The business model is pre-commercial biotech, financed through venture capital (cumulative ~$37M across rounds including a $19M Series A-2 led by Prime Movers Lab in October 2023, with Juvenescence and Longevity Vision Fund also participating), non-dilutive grants (Breakthrough T1D), and strategic co-development partnerships with iTolerance (immune tolerance) and Imagine Pharma (Type 1 diabetes). Distribution, when commercial, will occur through transplant centers and hospitals; the lead Phase 2a trial is being run at Houston Methodist Hospital with Dr. Constance Mobley as principal investigator.

The company was co-founded by CEO Michael Hufford (FDA regulatory and clinical development veteran), transplant surgeon Dr. Paulo Fontes (former UPMC Liver Transplant Program Director), and CSO Dr. Eric Lagasse, the world leader in ectopic transplantation research with 30+ years, 60+ publications, and 11,000+ citations, who developed the underlying technology at the University of Pittsburgh's McGowan Institute. Operating with 1-10 employees, LyGenesis sources non-transplantable donor organs from the International Institute for the Advancement of Medicine (IIAM) and processes them under cGMP; a previously pursued merger with AgeX Therapeutics was terminated in July 2021.

Short descriptiontext

LyGenesis is a clinical-stage cell therapy company developing allogeneic therapies that use patients' lymph nodes as bioreactors to grow functioning ectopic organs, with a lead Phase 2a liver program for end-stage liver disease and pipeline programs in thymus, pancreas, kidneys, and inborn errors of metabolism.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, organ regeneration medicine, liver disease treatment, regenerative cell therapy, lymph node bioreactor
Industry1 code
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Commercialization
TypeOne Time License
Description

LyGenesis is a clinical-stage biotechnology company developing allogeneic cell therapies. The company does not currently have commercialized products or revenue. Future revenue is anticipated from commercialization of its cell therapy pipeline including LYG-LIV-001 for end-stage liver disease, once clinical trials are successful and regulatory approvals are obtained.

lygenesis.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LyGenesis is a clinical-stage biotechnology company developing allogeneic cell therapies that leverage patients' lymph nodes as in vivo bioreactors to grow functioning ectopic organs. Its lead therapy LYG-LIV-001 uses donor-derived hepatocytes transplanted into mesenteric lymph nodes via endoscopic ultrasound to regenerate ectopic liver tissue for end-stage liver disease patients, with one donated liver capable of treating up to 75 patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • One donated liver can treat up to 75 patients with end-stage liver disease
+4 more records
Product overview1 text field

LyGenesis is a clinical-stage cell therapy company that has developed a platform technology using the patient's lymph nodes as in vivo bioreactors to grow functioning ectopic organs. The company's lead product is LYG-LIV-001, an allogeneic cell therapy for end stage liver disease currently in Phase 2a clinical trials. The platform enables one donated liver to treat dozens of patients, using an outpatient endoscopic ultrasound procedure for transplantation. The broader pipeline includes programs for thymus regeneration (aging/immune tolerance), pancreas regeneration (Type 1 diabetes), kidney regeneration (end stage renal disease), and inborn errors of metabolism (orphan pediatric indications). The company also has a second-generation therapy (LYG-LIV-100) in development with iTolerance for immune suppression-free organ regeneration.

Product and service5 records
1LYG-LIV-001
CategoryAllogeneic Cell Therapy - Liver
Description

Allogeneic cell therapy for end-stage liver disease (ESLD) that uses donor-derived hepatocytes to regenerate ectopic liver tissue inside the patient's upper abdominal lymph nodes. The therapy is created from donated but unmatched livers, processed under cGMP, and transplanted via outpatient endoscopic ultrasound. Currently in Phase 2a clinical trials (ClinicalTrials.gov NCT04496479), regulated as an FDA Section 351 Human Cellular Therapy/Product. One donated liver can treat up to 75 patients.

2Thymus Program
CategoryAllogeneic Cell Therapy - Thymus
Description

Cell therapy program focused on ectopic thymus development for aging-related immune decline and immune tolerance induction, currently in preclinical/POC completed stage. Investigates growth of ectopic thymus tissue in lymph nodes to restore immune function.

3Pancreas Program
CategoryAllogeneic Cell Therapy - Pancreas
Description

Cell therapy program focused on ectopic pancreas development for treatment of Type 1 diabetes, utilizing the lymph node as a bioreactor to grow functioning pancreatic tissue. Developed in collaboration with Imagine Pharma using T1D Activated Islet Progenitor Cells.

4Kidney Program
CategoryAllogeneic Cell Therapy - Kidney
Description

Cell therapy program focused on ectopic kidney development for treatment of end-stage renal disease, leveraging the lymph node's ability to promote vascularization for engrafted kidney tissues. Currently in POC completed stage.

5Inborn Errors of Metabolism Program
CategoryAllogeneic Cell Therapy - Orphan Pediatric
Description

Novel combination drug-biologic product for orphan pediatric indications involving inborn errors of metabolism, with lead indication for Maple Syrup Urine Disease (MSUD), affecting 1 in 185,000 newborns. Utilizes a hydrogel with growth factors and a proprietary patent-pending surgical catheter for engraftment under the liver capsule.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

Houston Methodist Hospital is a clinical trial site for LyGenesis's Phase 2a clinical trial. Dr. Constance Mobley serves as Principal Investigator and Associate Director of Liver Transplantation at Houston Methodist J.C. Walter Jr. Transplant Center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

Joint research collaboration to develop novel cell therapies for Type 1 diabetes. The collaboration leverages Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) combined with LyGenesis's lymph node bioreactor platform. Both companies are Pittsburgh-based biotechs working to advance preclinical proof of concept.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

Joint research collaboration to evaluate iTOL-201 (combining iTolerance's SA FasL immune tolerance platform with LyGenesis's liver cell therapy) to enable ectopic livers to be grown without need for immune suppression. The collaboration has generated in vitro data and is progressing toward animal proof of concept.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-01
Description

LyGenesis was founded based on research from Dr. Eric Lagasse's laboratory at the University of Pittsburgh's McGowan Institute for Regenerative Medicine. Dr. Lagasse serves as Associate Professor in the Department of Pathology and Director of the Cancer Stem Cell Center at McGowan.

5International Institute for the Advancement of Medicine (IIAM)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-01
Description

IIAM provides non-transplantable organs to the medical research community. LyGenesis sources donated but unmatched livers from IIAM for processing into cell therapies.

lygenesis.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

United Therapeutics is a leading player in organ transplantation and regenerative medicine (including lung, kidney, and xenotransplantation programs), making it a broad incumbent comparable to LyGenesis's mission of addressing organ failure and shortage.

TypeDirect peer
Description

Sana is a clinical-stage cell therapy company developing allogeneic hypoimmune cell therapies for multiple indications, comparable to LyGenesis's allogeneic cell therapy platform and pipeline breadth.

TypeDirect peer
Description

Vertex is developing VX-880, an allogeneic stem cell-derived islet cell therapy for Type 1 diabetes — directly comparable to LyGenesis's pancreas/T1D program and the broader allogeneic cell therapy modality in severe disease indications.

TypeBroad incumbent
Description

Humacyte is a regenerative medicine company developing bioengineered human tissues and vessels, comparable as a broad incumbent in the regenerative medicine / tissue engineering space addressing organ and vascular replacement.

TypeEmerging player
Description

eGenesis is developing genetically engineered porcine organs for xenotransplantation as an alternative solution to the donor organ shortage that LyGenesis's ectopic organ regeneration platform also targets.

6Sigilon Therapeutics
TypeDirect peer
Description

Sigilon developed encapsulated cell therapies (e.g., for Type 1 diabetes and lysosomal storage diseases) using allogeneic cells, comparable in modality (allogeneic cell therapy for chronic disease) and target indications to LyGenesis.

TypeEmerging player
Description

ProKidney is developing autologous cell therapy (REACT) for chronic kidney disease, directly comparable as a cell therapy targeting renal indications overlapping with LyGenesis's kidney program.

8Talaris Therapeutics
TypeEmerging player
Description

Talaris developed cell therapy (FCR001) to induce immune tolerance in organ transplant recipients, comparable in the intersection of cell therapy and transplant immunology, an area central to LyGenesis's iTolerance collaboration.

TypeBroad incumbent
Description

MiMedx is a commercial-stage regenerative medicine company with placental tissue allografts, comparable as a broad incumbent in regenerative medicine and allograft-based therapies addressing large unmet needs.

TypeEmerging player
Description

Seraxis is developing stem cell-derived islet cell therapies for Type 1 diabetes, comparable as an emerging player in the same disease space as LyGenesis's pancreas/T1D program.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LyGenesis

Regenerative Medicinelygenesis.com

LyGenesis is a clinical-stage cell therapy company developing allogeneic therapies that use patients' lymph nodes as bioreactors to grow functioning ectopic organs, with a lead Phase 2a liver program for end-stage liver disease and pipeline programs in thymus, pancreas, kidneys, and inborn errors of metabolism.

What LyGenesis does

LyGenesis is a clinical-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, developing allogeneic cell therapies that use a patient's own lymph nodes as in vivo bioreactors to grow functioning ectopic organs. The company's lead program, LYG-LIV-001, is an allogeneic liver cell therapy for end-stage liver disease currently in Phase 2a clinical trials (NCT04496479); one donated, otherwise-unmatched liver can potentially treat up to 75 patients via outpatient endoscopic ultrasound engraftment into mesenteric lymph nodes, upending the supply-demand economics of organ transplantation. The platform is being extended to additional organ programs: thymus regeneration (aging and immune tolerance, proof of concept completed), ectopic pancreas for Type 1 diabetes, ectopic kidneys for end-stage renal disease, and a combination drug-biologic product for inborn errors of metabolism led by Maple Syrup Urine Disease.

LyGenesis makes money, in the long run, by commercializing its cell therapies once clinical readouts and regulatory approvals are obtained; today it has no commercial revenue and no publicly disclosed pricing. The business model is pre-commercial biotech, financed through venture capital (cumulative ~$37M across rounds including a $19M Series A-2 led by Prime Movers Lab in October 2023, with Juvenescence and Longevity Vision Fund also participating), non-dilutive grants (Breakthrough T1D), and strategic co-development partnerships with iTolerance (immune tolerance) and Imagine Pharma (Type 1 diabetes). Distribution, when commercial, will occur through transplant centers and hospitals; the lead Phase 2a trial is being run at Houston Methodist Hospital with Dr. Constance Mobley as principal investigator.

The company was co-founded by CEO Michael Hufford (FDA regulatory and clinical development veteran), transplant surgeon Dr. Paulo Fontes (former UPMC Liver Transplant Program Director), and CSO Dr. Eric Lagasse, the world leader in ectopic transplantation research with 30+ years, 60+ publications, and 11,000+ citations, who developed the underlying technology at the University of Pittsburgh's McGowan Institute. Operating with 1-10 employees, LyGenesis sources non-transplantable donor organs from the International Institute for the Advancement of Medicine (IIAM) and processes them under cGMP; a previously pursued merger with AgeX Therapeutics was terminated in July 2021.

LyGenesis firmographics

Firmographics
Name
LyGenesis
Legal name
LyGenesis, Inc.
Website
https://lygenesis.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
LyGenesis is a clinical-stage cell therapy company developing allogeneic therapies that use patients' lymph nodes as bioreactors to grow functioning ectopic organs, with a lead Phase 2a liver program for end-stage liver disease and pipeline programs in thymus, pancreas, kidneys, and inborn errors of metabolism.
Ownership category
akta.pro rank

LyGenesis industry classification

Industry
Product category
Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Allogeneic cell therapy
  • Organ regeneration medicine
  • Liver disease treatment
  • Regenerative cell therapy
  • Lymph node bioreactor

Where LyGenesis is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LyGenesis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Cell Therapy Commercialization: LyGenesis is a clinical-stage biotechnology company developing allogeneic cell therapies. The company does not currently have commercialized products or revenue. Future revenue is anticipated from commercialization of its cell therapy pipeline including LYG-LIV-001 for end-stage liver disease, once clinical trials are successful and regulatory approvals are obtained.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

LyGenesis product offering

Product offering

Core offering

LyGenesis is a clinical-stage biotechnology company developing allogeneic cell therapies that leverage patients' lymph nodes as in vivo bioreactors to grow functioning ectopic organs. Its lead therapy LYG-LIV-001 uses donor-derived hepatocytes transplanted into mesenteric lymph nodes via endoscopic ultrasound to regenerate ectopic liver tissue for end-stage liver disease patients, with one donated liver capable of treating up to 75 patients.

Product overview

LyGenesis is a clinical-stage cell therapy company that has developed a platform technology using the patient's lymph nodes as in vivo bioreactors to grow functioning ectopic organs. The company's lead product is LYG-LIV-001, an allogeneic cell therapy for end stage liver disease currently in Phase 2a clinical trials. The platform enables one donated liver to treat dozens of patients, using an outpatient endoscopic ultrasound procedure for transplantation. The broader pipeline includes programs for thymus regeneration (aging/immune tolerance), pancreas regeneration (Type 1 diabetes), kidney regeneration (end stage renal disease), and inborn errors of metabolism (orphan pediatric indications). The company also has a second-generation therapy (LYG-LIV-100) in development with iTolerance for immune suppression-free organ regeneration.

Differentiator

Problem solved

Functional benefit

Products and services

  • LYG-LIV-001 Allogeneic cell therapy for end-stage liver disease (ESLD) that uses donor-derived hepatocytes to regenerate ectopic liver tissue inside the patient's upper abdominal lymph nodes. The therapy is created from donated but unmatched livers, processed under cGMP, and transplanted via outpatient endoscopic ultrasound. Currently in Phase 2a clinical trials (ClinicalTrials.gov NCT04496479), regulated as an FDA Section 351 Human Cellular Therapy/Product. One donated liver can treat up to 75 patients.
  • Thymus Program Cell therapy program focused on ectopic thymus development for aging-related immune decline and immune tolerance induction, currently in preclinical/POC completed stage. Investigates growth of ectopic thymus tissue in lymph nodes to restore immune function.
  • Pancreas Program Cell therapy program focused on ectopic pancreas development for treatment of Type 1 diabetes, utilizing the lymph node as a bioreactor to grow functioning pancreatic tissue. Developed in collaboration with Imagine Pharma using T1D Activated Islet Progenitor Cells.
  • Kidney Program Cell therapy program focused on ectopic kidney development for treatment of end-stage renal disease, leveraging the lymph node's ability to promote vascularization for engrafted kidney tissues. Currently in POC completed stage.
  • Inborn Errors of Metabolism Program Novel combination drug-biologic product for orphan pediatric indications involving inborn errors of metabolism, with lead indication for Maple Syrup Urine Disease (MSUD), affecting 1 in 185,000 newborns. Utilizes a hydrogel with growth factors and a proprietary patent-pending surgical catheter for engraftment under the liver capsule.

Quantifiable outcome

  • One donated liver can treat up to 75 patients with end-stage liver disease
  • +4 more outcomes

Companies that use LyGenesis

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles2 records

LyGenesis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

LyGenesis partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Houston Methodist HospitalcoreStrategic or Co-development Partner · 1 March 2025Houston Methodist Hospital is a clinical trial site for LyGenesis's Phase 2a clinical trial. Dr. Constance Mobley serves as Principal Investigator and Associate Director of Liver Transplantation at Houston Methodist J.C. Walter Jr. Transplant Center.
  • Imagine PharmacoreStrategic or Co-development Partner · 1 April 2023Joint research collaboration to develop novel cell therapies for Type 1 diabetes. The collaboration leverages Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) combined with LyGenesis's lymph node bioreactor platform. Both companies are Pittsburgh-based biotechs working to advance preclinical proof of concept.
  • iTolerancecoreStrategic or Co-development Partner · 1 June 2022Joint research collaboration to evaluate iTOL-201 (combining iTolerance's SA FasL immune tolerance platform with LyGenesis's liver cell therapy) to enable ectopic livers to be grown without need for immune suppression. The collaboration has generated in vitro data and is progressing toward animal proof of concept.
  • University of Pittsburgh / McGowan Institute for Regenerative MedicinecoreStrategic or Co-development Partner · 1 August 2020LyGenesis was founded based on research from Dr. Eric Lagasse's laboratory at the University of Pittsburgh's McGowan Institute for Regenerative Medicine. Dr. Lagasse serves as Associate Professor in the Department of Pathology and Director of the Cancer Stem Cell Center at McGowan.
  • International Institute for the Advancement of Medicine (IIAM)coreStrategic or Co-development Partner · 1 August 2020IIAM provides non-transplantable organs to the medical research community. LyGenesis sources donated but unmatched livers from IIAM for processing into cell therapies.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

LyGenesis competitors and assessment

Company assessment

Broad incumbents

  • United Therapeutics: United Therapeutics is a leading player in organ transplantation and regenerative medicine (including lung, kidney, and xenotransplantation programs), making it a broad incumbent comparable to LyGenesis's mission of addressing organ failure and shortage.
  • Humacyte: Humacyte is a regenerative medicine company developing bioengineered human tissues and vessels, comparable as a broad incumbent in the regenerative medicine / tissue engineering space addressing organ and vascular replacement.
  • MiMedx: MiMedx is a commercial-stage regenerative medicine company with placental tissue allografts, comparable as a broad incumbent in regenerative medicine and allograft-based therapies addressing large unmet needs.

Direct peers

  • Sana Biotechnology: Sana is a clinical-stage cell therapy company developing allogeneic hypoimmune cell therapies for multiple indications, comparable to LyGenesis's allogeneic cell therapy platform and pipeline breadth.
  • Vertex Pharmaceuticals: Vertex is developing VX-880, an allogeneic stem cell-derived islet cell therapy for Type 1 diabetes — directly comparable to LyGenesis's pancreas/T1D program and the broader allogeneic cell therapy modality in severe disease indications.
  • Sigilon Therapeutics: Sigilon developed encapsulated cell therapies (e.g., for Type 1 diabetes and lysosomal storage diseases) using allogeneic cells, comparable in modality (allogeneic cell therapy for chronic disease) and target indications to LyGenesis.

Emerging players

  • eGenesis: eGenesis is developing genetically engineered porcine organs for xenotransplantation as an alternative solution to the donor organ shortage that LyGenesis's ectopic organ regeneration platform also targets.
  • ProKidney: ProKidney is developing autologous cell therapy (REACT) for chronic kidney disease, directly comparable as a cell therapy targeting renal indications overlapping with LyGenesis's kidney program.
  • Talaris Therapeutics: Talaris developed cell therapy (FCR001) to induce immune tolerance in organ transplant recipients, comparable in the intersection of cell therapy and transplant immunology, an area central to LyGenesis's iTolerance collaboration.
  • Seraxis: Seraxis is developing stem cell-derived islet cell therapies for Type 1 diabetes, comparable as an emerging player in the same disease space as LyGenesis's pancreas/T1D program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

LyGenesis social profiles

Digital presence

LyGenesis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LyGenesis leadership team

Management profile

Number of profiles

Profiles8 records

LyGenesis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LyGenesis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LyGenesis

What does LyGenesis do?

LyGenesis is a clinical-stage biotechnology company developing allogeneic cell therapies that leverage patients' lymph nodes as in vivo bioreactors to grow functioning ectopic organs. Its lead therapy LYG-LIV-001 uses donor-derived hepatocytes transplanted into mesenteric lymph nodes via endoscopic ultrasound to regenerate ectopic liver tissue for end-stage liver disease patients, with one donated liver capable of treating up to 75 patients.

Is LyGenesis a public or private company?

LyGenesis is a private company. It is classified as venture growth investor backed and is currently operating.

When was LyGenesis founded?

LyGenesis was founded in 2017. It employs 1 to 10 people.

Where is LyGenesis based?

LyGenesis is headquartered in Pittsburgh, United States, in the North America region.

How does LyGenesis make money?

One revenue line is on record: cell Therapy Commercialization.

Who are LyGenesis's main competitors?

Broad incumbents on record are United Therapeutics, Humacyte and MiMedx. Direct peers are Sana Biotechnology, Vertex Pharmaceuticals and Sigilon Therapeutics. Emerging players are eGenesis, ProKidney, Talaris Therapeutics and Seraxis.

Does LyGenesis have an API?

No public API is recorded for LyGenesis.

What industry is LyGenesis in?

LyGenesis's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestVector Science and Therapeutics Corp. signs amended, 10-year manufacturing and testing agreement with Lyogenesis HoldingsVector Science and Therapeutics Corp. has signed an amended 10-year manufacturing and testing agreement with Lyogenesis Holdings. The deal establishes a long-term partnership for the production and evaluation of Vector Science's therapeutic products. This agreement secures ongoing supply chain capabilities for the biotechnology firm.PR NewswireLyGenesis Receives Award from Breakthrough T1D® to Fund a Research Project to Induce Immune Tolerance to Pancreatic Islet TransplantationLyGenesis, a clinical-stage biotechnology company headquartered in Pittsburgh, announced receiving a research award from Breakthrough T1D to support its thymus program investigating immune tolerance induction for allogeneic pancreatic islet transplantation in Type 1 diabetes. The pre-clinical research will be led by Dr. Eric Lagasse, Chief Scientific Officer at LyGenesis and Professor of Pathology at the University of Pittsburgh, building on foundational work in thymic biology and immune reprogramming. The award reinforces LyGenesis's expanding cell therapy platform, which currently includes programs for ectopic thymus, pancreas, and kidney development alongside its lead Phase 2a trial for end-stage liver disease.TechBullionSergey Young Investor: Why Longevity Became Personal for HimSergey Young, a venture investor, launched the Longevity Vision Fund in 2019 with approximately $100 million to invest in companies focused on healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine. The fund has built a portfolio of nearly twenty companies including Freenome, Insilico Medicine, Fountain Life, Tessera Therapeutics, and LyGenesis, and has gained recognition including Fast Company's 'World Changing Ideas' distinction. Beyond investing, Young serves on the board of the American Federation for Aging Research, supports Healthspan XPRIZE, and authored a bestselling book on longevity science, positioning himself as a leading public advocate for evidence-based approaches to extending healthy years of life.New ScientistTherapy that turns lymph nodes into livers gets first human trialLyGenesis has administered an experimental therapy to a human patient for the first time, injecting donated liver cells into a lymph node to create a miniature functioning liver. The company is currently testing this procedure on 12 patients with end-stage liver disease, with results expected in several months. If successful, the treatment could significantly reduce the waitlist for liver transplants by allowing one donor organ to treat multiple recipients.WIREDThis Bag of Cells Could Grow New Livers Inside of PeopleBiotech company LyGenesis has administered the first injection of donor liver cells into a human volunteer in Houston as part of a clinical trial for end-stage liver disease. The experimental treatment aims to grow miniature livers inside patients' lymph nodes to alleviate organ shortages, with plans to test varying cell doses on 12 adults. If successful, this approach could offer a life-saving alternative to traditional liver transplants by utilizing discarded donor organs.PR NewswireLyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver DiseaseLyGenesis has dosed the first patient in its Phase 2a clinical trial evaluating an allogeneic regenerative cell therapy for end-stage liver disease, transplanting hepatocytes into the patient's lymph nodes to grow functional ectopic liver tissue. The therapy could enable one donated liver to treat dozens of ESLD patients, potentially addressing the organ supply-demand imbalance where up to half of eligible patients are medically ineligible for transplants and approximately 12% on the waitlist die annually. The open-label, dose-escalation trial is recruiting 12 patients who will be monitored over one year to assess safety, tolerability, and efficacy.Pulse 2.0LyGenesis: $19 Million Closed To Develop Cell TherapiesLyGenesis has closed a $19 million Series A-2 financing round led by Prime Movers Lab with follow-on participation from Juvenescence. The funding will support the completion of its Phase 2a clinical trial for cell therapies targeting end-stage liver disease and other conditions. This investment enables the company to advance its pipeline of regenerative treatments using lymph nodes as bioreactors.VC News DailyLyGenesis Raises $19M Series A-2 RoundLyGenesis announced the raising of over $19 million in a Series A-2 financing round led by Prime Movers Lab with follow-on funding from Juvenescence. The capital will be used to complete its Phase 2a clinical trial for end-stage liver disease and advance its pipeline of cell therapies for conditions such as type 1 diabetes and aging.PR NewswireLyGenesis Raises $19M in Series A-2 Funding Led by Prime Movers LabLyGenesis has raised more than $19 million in a Series A-2 funding round led by Prime Movers Lab, with additional investment from Juvenescence. The capital will be used to complete the ongoing Phase 2a clinical trial for its LYG-LIV-001 cell therapy targeting end-stage liver disease and to advance its broader pipeline of regenerative therapies. This financing supports LyGenesis's development of allogeneic cell therapies that utilize lymph nodes as bioreactors to grow functional ectopic organs.FinSMEsLyGenesis Raises $19M in Series A-2 FundingLyGenesis, a Pittsburgh-based clinical-stage biotechnology company, raised $19 million in Series A-2 funding led by Prime Movers Lab with participation from Juvenescence. The company intends to use the capital to complete its Phase 2a clinical trial for end-stage liver disease and advance its pipeline of cell therapies aimed at regrowing ectopic organs.